ClinicalTrials.gg

Program

mirikizumab

Also written as “Mirikizumab”, “LY3074828” and “Mirikizumab IV”.

Its studies are mostly in Colitis, Ulcerative · Psoriasis · Crohn Disease · Breast Feeding, led by 2 companies.

Furthest: phase 4, since May 21, 202636 company-led studies, 7 open or runningNext primary completion: Feb 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly356 open or runningphase 4since May 21, 2026Sep 18, 2013Feb 2027phase 1 · NCT07446101
Rubix LS11 open or runningphase 4since Jul 1, 2025Jul 1, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 22 studies since Sep 18, 2013.

  1. Jul 10, 2020Phase 3 study in Colitis, UlcerativeEli Lilly · NCT04469062
  2. Sep 10, 2020Phase 1 study in HealthyEli Lilly · NCT04548219 · 60 enrolled · United States
  3. Oct 28, 2020Phase 1 study in HealthyEli Lilly · NCT04607733 · 240 enrolled · United States
  4. Apr 12, 2021Phase 3 study in Colitis, UlcerativeEli Lilly · NCT04844606 · 150 planned · United States, Austria, Belgium and more
  5. Oct 1, 2021Phase 1 study in HealthyEli Lilly · NCT05069896 · 237 enrolled · United States
  6. Aug 19, 2022Phase 3 study in Crohn DiseaseEli Lilly · NCT05509777 · 90 planned · United States, Austria, Belgium and more
  7. Aug 24, 2022Phase 1 study in HealthyEli Lilly · NCT05515601 · 396 enrolled · United States
  8. Dec 1, 2022Phase 1 study in HealthyEli Lilly · NCT05644353 · 450 enrolled · United States
  9. Feb 8, 2023Phase 3 study in Colitis, UlcerativeEli Lilly · NCT05767021 · 172 enrolled · United States, Belgium, Czechia and more
  10. Mar 13, 2023Phase 3 study in Colitis, UlcerativeEli Lilly · NCT05784246 · 63 enrolled · United States, Belgium, Canada and more
  11. Jun 21, 2024Phase 1 study in HealthyEli Lilly · NCT06475729 · 498 enrolled · United States
  12. Jul 1, 2025Rubix LS's first study: phase 4 study in Crohn DiseaseNew to Rubix LSRubix LS · NCT07059130 · 150 planned · United States
  13. Feb 26, 2026Phase 1 study in HealthyEli Lilly · NCT07446101 · 450 planned · United States
  14. May 21, 2026Phase 4 study in Breast FeedingEli Lilly · NCT07612267 · 14 planned · United States, Canada, Denmark and more

Ahead

  1. Feb 2027Primary completion: phase 1 study in HealthyEli Lilly · NCT07446101
  2. Dec 2027Primary completion: phase 3 study in Crohn DiseaseEli Lilly · NCT05509777
  3. Sep 2028Primary completion: phase 4 study in Breast FeedingEli Lilly · NCT07612267
  4. Dec 2030Primary completion: phase 3 study in Colitis, UlcerativeEli Lilly · NCT04844606

TargetBeta

IL12B →IL23A →read by rule
“Interleukin-23 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
risankizumabruleAbbViephase 468
guselkumabruleJohnson & Johnsonphase 460

Studies

All 36 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07612267Breast Feeding · United States, Canada, Denmark and more4RecruitingEli LillySep 202814
NCT07446101Healthy · United States1RecruitingEli LillyFeb 2027450
NCT07059130Crohn Disease · United States4Not yet recruitingRubix LSJan 1, 2026150
NCT06475729Healthy · United States1CompletedEli LillyDec 27, 2024498
NCT05784246Colitis, Ulcerative · United States, Belgium, Canada and more3CompletedEli LillyMay 1, 202663
NCT05767021Colitis, Ulcerative · United States, Belgium, Czechia and more3CompletedEli LillyAug 9, 2024172
NCT05644353Healthy · United States1CompletedEli LillyMay 25, 2023450
NCT05515601Healthy · United States1CompletedEli LillyFeb 20, 2023396
NCT05509777Crohn Disease · United States, Austria, Belgium and more3RecruitingEli LillyDec 202790
NCT05069896Healthy · United States1CompletedEli LillyJun 22, 2022237
NCT04844606Colitis, Ulcerative · United States, Austria, Belgium and more3RecruitingEli LillyDec 2030150
NCT04607733Healthy · United States1CompletedEli LillyMay 17, 2021240
NCT04548219Healthy · United States1CompletedEli LillyJan 11, 202160
NCT04469062Colitis, Ulcerative3WithdrawnEli LillyMar 13, 20240
NCT04232553Crohn Disease · United States, Argentina, Australia and more3Active, not recruitingEli LillyNov 28, 2024996
NCT04137380Healthy · China1CompletedEli LillyDec 11, 202060
NCT04004611Colitis, Ulcerative · United States, Canada, Israel and more2CompletedEli LillyMar 15, 202326
NCT03926130Crohn Disease · United States, Argentina, Australia and more3CompletedEli LillyAug 23, 20231,158
NCT03718884Psoriasis · United States1CompletedEli LillyOct 28, 201929
NCT03748940Healthy · United Kingdom1CompletedEli LillyJun 18, 201960
NCT03662100Healthy · United States1CompletedEli LillyJan 25, 201966
NCT03556202Psoriasis · United States, Argentina, Australia and more3TerminatedEli LillyFeb 7, 20221,936
NCT03535194Psoriasis · United States, Argentina, Australia and more3CompletedEli LillyMar 5, 20201,484
NCT03524092Colitis, Ulcerative · United States, Argentina, Australia and more3CompletedEli LillyNov 3, 20211,328
NCT03519945Colitis, Ulcerative · United States, Argentina, Australia and more3Active, not recruitingEli LillyMar 4, 20261,058
NCT03518086Colitis, Ulcerative · United States, Argentina, Australia and more3CompletedEli LillyJan 21, 20211,281
NCT03482011Psoriasis · United States, Germany, Japan and more3CompletedEli LillyMar 21, 2019530
NCT03456713Healthy · United States1CompletedEli LillyAug 13, 201872
NCT03220126Healthy · United Kingdom1CompletedEli LillyFeb 23, 201872
NCT03188510Healthy · United States1CompletedEli LillyNov 27, 201754
NCT03053622Healthy · United Kingdom1CompletedEli LillyApr 3, 201867
NCT02899988Plaque Psoriasis · United States, Canada, Germany and more2CompletedEli LillyJun 19, 2017205
NCT02891226Crohn Disease · United States, Australia, Belgium and more2CompletedEli LillyDec 11, 2018191
NCT02589665Colitis, Ulcerative · United States, Australia, Belgium and more2CompletedEli LillyDec 19, 2017249
NCT02568423Healthy · United States1CompletedEli LillyJul 16, 201851
NCT01947933Psoriasis · Canada1CompletedEli LillyFeb 201545

How it is read

Names in the registry

  • “Mirikizumab”, 24 entries
  • “LY3074828”, 6 entries
  • “Mirikizumab IV”, 3 entries
  • “Mirikizumab SC”, 3 entries
  • “Mirikizumab - SC”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.